Recent News
Read ArticleEULAR has updated its recommendations for the management of Behçet’s syndrome, the last being published in 2018. The current update carries no recommendations from the previous version: seven recommendations have content modifications, four have minor wording amends, and one is entirely new.
Missed #RheumNowLive 2026?
The full meeting is now available On Demand.
✔ 2 days of clinical updates
✔ Expert faculty panels
✔ Speaker slides
✔ Pre-learn modules
Watch anytime for $250.
Learn from the meeting that kicks off the year in rheumatology.
🔗 Access here: https://t.co/GJwap25PVU
Dr. John Cush @RheumNow ( View Tweet)
Mortality in Rheumatoid Arthritis: A Story of Decline, Delay, or Plateau? Dr. Elena Myasoedova
https://t.co/YoQmrXHZif https://t.co/7v82hHvvZv
Dr. John Cush @RheumNow ( View Tweet)
Rheumatology Pitfalls (3.20.2026)
Dr. Jack Cush reviews the regulatory actions, news and journal reports from this past week on RheumNow.
https://t.co/VkUzxrWq8F https://t.co/9bkwvHwoN0
Dr. John Cush @RheumNow ( View Tweet)
Predictors of Response in Lupus
A systematic review suggests that traditional measures (serologies and disease activity) are superior to biomarkers in predicting response to biologics in systemic lupus erythematosus (SLE) patients.
https://t.co/7YuYpoDctR https://t.co/J5VLrkDQ6G
Dr. John Cush @RheumNow ( View Tweet)
Long-Term Bimekizumab Safety Data
Adverse effects from bimekizumab through 2 years or more of treatment for psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA) were about as expected from shorter-term data, results from long-term extension studies indicated. https://t.co/AaJxewNQmQ
Dr. John Cush @RheumNow ( View Tweet)
Rush University MDHAQ surveys done on 1,337 pts (excluding primary FM), identified 30% w/ anxiety, 24% depression, 25% fibromyalgia, & 44% w any 3 of these. In this 44%, HIGHER pain (7 vs 4) and RAPID3 (17 vs 8.2) vs those without FM, anxiety, or depression (p< 0.001). https://t.co/GzZ0LZKPPR
Dr. John Cush @RheumNow ( View Tweet)
Prednisone use in Alberta primary care 546 #RA pts - 40% of PCP RA Rx w/ 1 or more prednisone Rx. 41% Rx w/ both Pred + DMARD, w/ 44% on Pred median 124 day before DMARD. 66% continued Pred >1 yr after DMARD initiation. https://t.co/wrxQRP2TWN https://t.co/XxWpjafBsk
Links:
Dr. John Cush @RheumNow ( View Tweet)
A retrospective cohort study of 195 renal Bx from 135 Lupus Nephritis pts, Mod-Severe interstitial fibrosis and tubular atrophy (IFTA) strongly assoc w/non-renal response & ESRD progression (HR 8.9) (also w/ age, SLE duration, prior LN flares, higher chronicity index) https://t.co/3JGLi5R5Fs
Dr. John Cush @RheumNow ( View Tweet)
RA pt on 7.5 mg/d Prednisone need hip replacement. What do you advise re: pred dose before TKR?
Dr. John Cush @RheumNow ( View Tweet)
"If you have a great 2nd act; the 3rd act writes itself". - Ron Shelton https://t.co/OFgISgu2qF
Dr. John Cush @RheumNow ( View Tweet)
JAMA Patient Education Page on JAMA Eosinophilic Fasciitis (EF). EF is rare, but begins with swelling and redness of the arms and/or legs. Later the skin thickens and develops the peau d' orange appearance. EF does not involve fingers or toes, & doesnt have Raynauds https://t.co/WEFFITtmQC
Dr. John Cush @RheumNow ( View Tweet)
A multi-center, retrospective chart review of 82 Still's disease pts (63% female; mean Dx age 6.4 ± 4 yrs; F/U ~2.8 yrs). When analyzing Dz course, 34% were monophasic, 46% polyphasic (higher-than-expected), 19.5% persistent Dz. non-monophasic predicted by active 3 mos from Dx https://t.co/XWJSsIE7Pn
Dr. John Cush @RheumNow ( View Tweet)
FDA has approved secukinumab (Cosentyx) for use pediatric patients (aged >12yrs) with moderate to severe hidradenitis suppurativa https://t.co/oX4LGU16QP
Dr. John Cush @RheumNow ( View Tweet)
You can change what comes to your attention. We can change the external and internal focus by being mindful of the triggers and amplifiers we consume. If you’re not happy with what your attention is bringing you, you can change it. - Seth Godin https://t.co/QsUxTmjX1U
Links:
Dr. John Cush @RheumNow ( View Tweet)
REVEAL, a 5-yr real-world study of 236 SLE pts initiating anifrolumab (basekbube SLEDAI-2K 7 for mucocutaneous (67%) & MSK (49%) dz. At 6 months, 26% achieved remission, 66% reached LLDAS, and 57% achieved LLDAS5. Authors claim rapid onset of action https://t.co/16OQatOcPj https://t.co/mU9aciCNcH
Dr. John Cush @RheumNow ( View Tweet)
Pitfalls of autoimmune serologic testing
Misuse of laboratory testing may lead to misdiagnoses and mismanagement; this is particulary prevalent when clinicians consider the use of the diagnostic use of serological autoimmune markers.
https://t.co/QDWTRgdlOh https://t.co/3hvM1OBcMC
Dr. John Cush @RheumNow ( View Tweet)
NEJM: Obinutuzumab in Active Systemic Lupus Erythematosus
A phase 3 trial of obinutuzumab, an anti-CD20 monoclonal antibody, showed potent B-cell depletion and clinical efficacy active systemic lupus erythematosus without evidence of nephritis.
https://t.co/OEuNAZlgzp https://t.co/yjUmJITAmQ
Dr. John Cush @RheumNow ( View Tweet)
FDA has accepted the supplemental biologics license application for use of interleukin-23 inhibitor tildrakizumab (Ilumya; Sun Pharma) in active psoriatic arthritis (PsA) in adults. https://t.co/cwqz9DoWsL https://t.co/ut0A4MwqW7
Dr. John Cush @RheumNow ( View Tweet)
FDA Approves Icotrokinra for Plaque Psoriasis
The FDA approved an oral IL-23 inhibitor, icotrokinra (Icotyde), for use in moderate-to-severe plaque psoriasis in adults and children 12 years of age and older who are candidates for systemic therapy or phototherapy, according to a https://t.co/q5b3TceFHx
Dr. John Cush @RheumNow ( View Tweet)
Video
From the Blog
Podcasts
Pitfalls in Rheumatology (3.20.2026)
STEP Talks from RNL26 Part #2-
STEP Talks from RNL26 Part #1
-
Rheumatoid Arthritis Faculty Panel Q&A
Therapeutic Updates
5-Year Results of an IL-23 Inhibitor in Patients With PsA
Sponsored by AbbVie Medical Affairs + Health Impact
Dr. Alvin Wells and Dr. Shikha Singla share their clinical perspectives on using an IL–23 inhibitor to manage patients with PsA throughout their treatment journey in the context of 5-year data from the KEEPsAKE trial program.
Read Post
Poster Hall
